Concepedia

Julien Mazieres

JM

Statistics

Publications

6

Citations

254

H-Index

6

Active since

2017

Affiliations

Hôpital Larrey(Current)

Institut Gustave Roussy

Hôpital Bichat-Claude-Bernard

Hospices Civils de Lyon

Intergroupe Francophone de Cancérologie Thoracique

Julien Mazieres is an author at Hôpital Larrey specializing in medicine, oncology, and pharmacology.

Publications per year

2017–2024

6

Publications

6

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 86 citations · Full text

, , +16

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

Julien Mazieres, Alexander Drilon, Laurent Mhanna et al. · Journal of Clinical Oncology · 2018 · 54 citations

, , +17

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 51 citations

, , +16

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 23 citations

, , +16

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).

Bob T. Li, Myung‐Ju Ahn, Kōichi Goto et al. · Journal of Clinical Oncology · 2022 · 21 citations

, , +10

1–5 of 6